| 22nd June 18h00 |
Nab-Paclitaxel: tumor targeted chemotherapy extending and improving the life of MBC patients
Speaker: Michelino De Laurentiis
Supported by Celgene |
| 22nd June 18h45 |
Where to go after Anthracyclines and Taxanes? Eribulin, extending life, extending options, in heavily pre-treated MBC
Chairman: Saverio Cinieri
Speaker: Christopher Twelves
Supported by Eisai |
| 23rd June 10h50 |
Full oral metronomic schedule of Vinorelbine and Capecitabine in metastatic breast cancer: a new age in therapy
Chairman: Franco Nolé
Speaker: Marina Cazzaniga
Supported by Pierre Fabre Pharma |
| 23rd June 13h30 |
Endocrine therapies in the Era of lapatinib: a personalized treatment for cancer patients
Chairman: Saverio Cinieri
Cross talk between endocrine and ErbB family pathways - Grazia Arpino
Lapatinib: a new way in the management of HR+/HER2+1st line MBC - Filippo Montemurro
Supported by GlaxoSmithKline |
| 23rd June 17h15 |
HER2: from the target to the current therapy toward a promising future
Chairman: Giuseppe Curigliano
Anti HER2 treatments: state of the art – Michelino De Laurentiis
Improving anti HER2 therapy: news and views for the future – Angelo Di Leo
Supported by Roche |
| 24th June 09h50 |
Hormonal Treatment for advance breast cancer: putting new data in the contest
Chairman: Saverio Cinieri
Speaker: Michelino De Laurentiis
Supported by Astrazeneca
|
| 24th June 12h35 |
Anti angiogenesis in breast cancer
Chairman: Saverio Cinieri
Anti angiogenic therapy in MBC: is it useful? – Laura Biganzoli
Angiogenesis in breast cancer: biomarkers for clinical use – Francesco Bertolini
Supported by Roche |
HOME PAGE
Wed, 22 june 2011